Noncarious cervical lesions: Response from a 25-year clinical follow-up study
STATEMENT OF PROBLEMThe etiology and diagnosis of noncarious cervical lesions (NCCLs) remain poorly understood.PURPOSEThe purpose of this clinical study was to examine NCCL progression in an existing group of participants, establish the incidence of new NCCLs in a 25-year follow-up study, and relate...
Gespeichert in:
Veröffentlicht in: | The Journal of prosthetic dentistry 2023-11 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | STATEMENT OF PROBLEMThe etiology and diagnosis of noncarious cervical lesions (NCCLs) remain poorly understood.PURPOSEThe purpose of this clinical study was to examine NCCL progression in an existing group of participants, establish the incidence of new NCCLs in a 25-year follow-up study, and relate them to possible risk factors, including occlusal factors.MATERIAL AND METHODSThirty-three participants who had completed a questionnaire about their habits, diet, and personal information were evaluated in this observational retrospective study. Impressions were made, and casts from 3 time periods (Phase I in 1996, Phase II in 1999, and Phase III in 2021) were scanned to obtain digital casts. The casts were then evaluated in a 3-dimensional analysis software program (Geomagic Control; 3D Systems) to establish digital comparisons between NCCLs and occlusal wear. Furthermore, data from an occlusal analysis device (T-Scan; Tekscan) collected in Phase I was used to analyze occlusal interferences relating to the progression of NCCLs. The statistical analysis applied nonparametric tests, followed by the assessment of the association between NCCLs and risk factors, including occlusal wear, through binary logistic regression (α=.05).RESULTSAt the end of Phase III, 7 new individuals with NCCLs were detected compared with Phase II. The median percentage progression of NCCLs per participant was 0.0% in Phase I, 7.1% in Phase II, and 35.7% in Phase III (P |
---|---|
ISSN: | 0022-3913 1097-6841 |
DOI: | 10.1016/j.prosdent.2023.11.001 |